88 related articles for article (PubMed ID: 7391989)
1. Plasma and myocardial tissue concentrations of UM-272 (N,N-dimethylpropranolol) after oral administration in dogs.
Patterson E; Stetson P; Lucchesi BR
J Pharmacol Exp Ther; 1980 Aug; 214(2):449-53. PubMed ID: 7391989
[TBL] [Abstract][Full Text] [Related]
2. Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.
Patterson E; Stetson P; Lucchesi BR
Pharmacology; 1983; 27(4):192-6. PubMed ID: 6634932
[TBL] [Abstract][Full Text] [Related]
3. Tissue digoxin concentrations at digoxin intoxication in normal, acutely hypokalemic, and acutely hyperglycemic dogs.
Gupta RD; Binnion PF
Physiol Chem Phys; 1976; 8(3):207-20. PubMed ID: 1013176
[TBL] [Abstract][Full Text] [Related]
4. Effect of 8-(3-diethylaminopropyl)-6,6-dimethyl-(2-phenyl-1 H-imidazo(4,5 h))isoquinoline-7,9-(6H)-dione dihydrochloride (AR-LH31) on experimental cardiac arrhythmias in dogs.
Kerr MJ; Harron DW; Wilson R; Shanks RG
Arzneimittelforschung; 1985; 35(1A):197-200. PubMed ID: 3838674
[TBL] [Abstract][Full Text] [Related]
5. Chronic ventricular tachyarrhythmias in the conscious dog: prevention by UM-272 (dimethylpropranolol).
Patterson E; Lucchesi BR
J Cardiovasc Pharmacol; 1981; 3(4):769-80. PubMed ID: 6167806
[TBL] [Abstract][Full Text] [Related]
6. Disopyramide plasma and myocardial tissue concentrations as they relate to antiarrhythmic activity.
Patterson E; Stetson P; Lucchesi BR
J Cardiovasc Pharmacol; 1979; 1(5):541-50. PubMed ID: 94410
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
8. [Early and late effects of adenosine in experimental ventricular tachycardia].
de Micheli A; Chávez Domínguez R; Iturralde Torres P; Pastelín G; Medrano GA
Rev Esp Cardiol; 2005 Feb; 58(2):159-66. PubMed ID: 15743562
[TBL] [Abstract][Full Text] [Related]
9. Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects.
Sintov A; Scott WA; Gallagher KP; Levy RJ
Pharm Res; 1990 Jan; 7(1):28-33. PubMed ID: 2300532
[TBL] [Abstract][Full Text] [Related]
10. Role of vagus in the antagonism of ouabain induced arrhythmias in dogs by beta-adrenoceptor antagonists and related drugs.
Alkondon M; Ray A; Sen P
J Pharm Pharmacol; 1984 Oct; 36(10):702-4. PubMed ID: 6150094
[TBL] [Abstract][Full Text] [Related]
11. Ventricular fibrillation in a conscious canine model--its prevention by UM-272.
Eller BT; Patterson E; Lucchesi BR
Eur J Pharmacol; 1983 Mar; 87(4):407-13. PubMed ID: 6852097
[TBL] [Abstract][Full Text] [Related]
12. A model to describe myocardial drug disposition in the dog.
Kates RE; Jaillon P
J Pharmacol Exp Ther; 1980 Jul; 214(1):31-6. PubMed ID: 7391969
[TBL] [Abstract][Full Text] [Related]
13. Myocardial disposition of amiodarone in the dog.
Latini R; Connolly SJ; Kates RE
J Pharmacol Exp Ther; 1983 Mar; 224(3):603-8. PubMed ID: 6827483
[TBL] [Abstract][Full Text] [Related]
14. Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro.
Hachisu M; Chen H; Soneda T; Fujishima K; Ishizuka T; Konno F
Drugs Exp Clin Res; 1995; 21(4):145-51. PubMed ID: 8529527
[TBL] [Abstract][Full Text] [Related]
15. R56865, an antiarrhythmic drug with class III effects that terminates ouabain induced ventricular tachycardia in an inverse rate dependent manner.
Vos MA; van Deursen RT; Gorgels AP; Leunissen JD; Wellens HJ
Cardiovasc Res; 1993 Aug; 27(8):1491-7. PubMed ID: 8221803
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic actions of UM-272 (Pranolium) on reentrant ventricular arrhythmias in postinfarction canine myocardium.
Gibson JK; Lucchesi BR
J Pharmacol Exp Ther; 1980 Aug; 214(2):347-53. PubMed ID: 7391982
[No Abstract] [Full Text] [Related]
17. [Antiarrhythmic properties of 3-(2-hydroxy-3 isopropylamino-propoxy)-3 phenyl-2 isoindolinone-1, (RS, SR) in the dog].
Detaille JY; Caillard CG; Mondot S; Louis JC; Julou L
C R Seances Acad Sci D; 1979 Feb; 288(5):555-8. PubMed ID: 108025
[TBL] [Abstract][Full Text] [Related]
18. Effects of magnesium and ethmozin on ventricular tachycardia induced by ouabain and ventricular pacing in conscious dogs with complete atrioventricular block.
Fazekas T; Vos MA; Leunissen JD; Wellens HJ
Acta Physiol Hung; 1993; 81(1):59-70. PubMed ID: 8178656
[TBL] [Abstract][Full Text] [Related]
19. Glucagon in prevention and abolition of ouabain-induced ventricular tachycardia in normokalemic and hypokalemic dogs.
Einzig S; Todd EP; Nicoloff DM; Lucas RV
Circ Res; 1971 Jul; 29(1):88-95. PubMed ID: 5561410
[No Abstract] [Full Text] [Related]
20. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
